Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors

Current Opinion in Gastroenterology

Volumn 26, Issue 4, 2010, Pages 367-378

  Hershcovici, Tiberiu ^a   Fass, Ronnie ^a,b  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Acid reflux; GERD; Heartburn; Proton pump inhibitors

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ADX 10059; ARBACLOFEN PLACARBIL; BACLOFEN; BOTULINUM TOXIN; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METABOTROPIC RECEPTOR ANTAGONIST; OMEPRAZOLE; PRODRUG; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; XP 19986;

ACUPUNCTURE; ANTIREFLUX OPERATION; BEDTIME DOSAGE; CLINICAL TRIAL; CONFUSION; DIZZINESS; DROWSINESS; ESOPHAGEAL PH MONITORING; ESOPHAGUS BIOPSY; EVENING DOSAGE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; LIFESTYLE MODIFICATION; LIVER DISEASE; LOWER ESOPHAGUS SPHINCTER PRESSURE; MORNING DOSAGE; NON EROSIVE REFLUX DISEASE; PATIENT COMPLIANCE; PH MEASUREMENT; REVIEW; SOMNOLENCE; TREATMENT FAILURE; TREMBLING; TREMOR; WEAKNESS; ESOPHAGOSCOPY; PATHOPHYSIOLOGY; RISK FACTOR;

ESOPHAGEAL PH MONITORING; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS; RISK FACTORS; TREATMENT FAILURE;

EID: 77954136996     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32833ae2be     Document Type: Review

References (98)

1. Inadomi JM, McIntyre L, Bernard L, et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98:1940-1944.
2. Gallup Organization. The 2000 Gallup Study of Consumers' Use of Stomach Relief Products. Princeton: Gallup Organization; 2000.
3. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656-664.
4. Chey WD, Mody RR, Wu EQ, et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin 2009; 25:1869-1878.
5. Fass R, Sampliner RE. Barrett's oesophagus: optimal strategies for prevention and treatment. Drugs 2003; 63:555-564.
6. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58:295-309.
7. Drossman D, editor. Rome III: the functional gastrointestinal disorders. Third Edition. McLean, VA: Degnon Associates, Inc.; 2006.
8. Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin Gastroenterol Hepatol 2008; 6:393-400.
9. Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10:252-257.
10. Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49:463-464.
11. Gunaratnam NT, Jessup TP, Inadomi J, et al. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Therapeut 2006; 23:1473-1477.
12. Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on acid suppressive therapy. Am J Gastroenterol 2008; 103:1090-1096.
13. Zerbib F, Duriez A, Roman S, et al. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008; 57:156-160.
14. Karamanolis G, Stevens W, Vos R, et al. Oesophageal tone and sensation in the transition zone between proximal striated and distal smooth muscle oesophagus. Neurogastroenterol Motil 2008; 20:291-297.
15. Lichtenstein DR, Cash BD, Davila R, et al. Role of endoscopy in the management of GERD. Gastrointest Endosc 2007; 66:219-224.
16. Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc 2010; 71:28-34.
17. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic eso-phagitis after treatment with omeprazole. Gastroenterology 1988; 95:903-912.
18. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. multicenter study. Gastroenterology. Gastroenterology 1992; 102:109-118.
19. Richter JE. How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol 2007; 4:658-664.
20. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007; 5:4-16.
21. van Malenstein H, Farre R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2008; 103:1021-1028.
22. Tobey NA, Carson JL, Alkiek RA, et al. Dilated intercellular spaces: a morphological feature of acid reflux: damaged human esophageal epithelium. Gastroenterology 1996; 111:1200-1205.
23. Caviglia R, Ribolsi M, Maggiano N, et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005; 100:543-548.
24. Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005; 128:771-778.
25. Knowles CH, Aziz Q. Visceral hypersensitivity in nonerosive reflux disease. Gut 2008; 57:674-683.
26. Farre R, Fornari F, Blondeau K, et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut 2010; 59:164-169.
27. Solcia E, Villani L, Luinetti O, et al. Red intercellular glycoconjugates and dilated intercellular spaces of esophageal epithelium in reflux disease. Virch-ows Arch 2000; 436:207-216.
28. Takubo K, Honma N, Aryal G, et al. Is there a set of histologic changes that are invariably reflux associated? Arch Pathol Lab Med 2005; 129:159-163.
29. Zentilin P, Savarino V, Mastracci L, et al. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol 2005; 100:2299-2306.
30. Ravelli AM, Villanacci V, Ruzzenenti N, et al. Dilated intercellular spaces: a major morphological feature of esophagitis. J Pediatr Gastroenterol Nutr 2006; 42:510-515.
31. Ribolsi M, Caviglia R, Gentile M, et al. Dilated intercellular space diameters of esophageal epithelium in NERD patients with typical symptoms resistant to PPI therapy (abstract). Gastroenterology 2007; 132:#935 [A-139].
32. Bautista JM, Wong WM, Pulliam G, et al. The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose antireflux medications. Dig Dis Sci 2005; 50:1909-1915.
33. Hirano I, Richter JE. Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668-685.
34. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91:1532-1538.
35. Fass R, Hell R, Sampliner RE, et al. Effect of ambulatory 24-h esophageal pH monitoring on reflux-provoking activities. Dig Dis Sci 1999; 44:2263-2269.
36. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100:283-289.
37. Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-h esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Digest Dis Sci 2008; 53:2387-2393.
38. Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol 2001; 96:2033-2040.
39. Mainie I, Tutuian R, Shay S, et al. Acid and nonacid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55:1398-1402.
40. Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6:521-524.
41. Hirano I, Zhang X, Pandolfino JE, et al. Bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005; 3:1083-1088.
42. Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93:763-767.
43. Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Therapeut 2002; 16:1309-1316.
44. Sifrim D, Castell DO, Dent J, et al. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, nonacid, and gas reflux. Gut 2004; 53:1024-1031.
45. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesopha-geal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120:1599-1606.
46. Katz P, Gideon RM, Tutuian R. Reflux symptoms on twice daily (BID) proton pump inhibitor (PPI) associated with non acid reflux; a manifestation of hypersensitive esophagus? (abstract). Am J Gastroenterol 2005; 128:#925 [A-130].
47. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101:1956-1963.
48. Pritchett JM, Aslam M, Slaughter JC, et al. Efficacy of esophageal impedance/ pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol 2009; 7:743-748.
49. Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off proton pump inhibitor? Am J Gastroenterol 2008; 103:2446-2453.
50. Pace F, Sangaletti O, Pallotta S, et al. Biliary reflux and nonacid reflux are two distinct phenomena: a comparison between 24-h multichannel intraesopha-geal impedance and bilirubin monitoring. Scand J Gastroenterol 2007; 42:1031-1039.
51. Siddiqui A, Rodriguez-Stanley S, Zubaidi S, et al. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005; 50:81-85.
52. Farre R, Van Malenstein MH, de Vos R, et al. Weakly acidic solutions containing pepsin and bile acids can increase significantly esophageal mucosa permeability (abstract). Gastroenterology 2007; 132:#S1897 [A-274].
53. Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99:981-988.
54. Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009; 104:2005-2013.
55. Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107:747-754.
56. Netzer P, Gut A, Brundler R, et al. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Aliment Pharmacol Therapeut 2001; 15:1375-1384.
57. Todd JA, Basu KK, de Caestecker JS. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus. Aliment Pharmacol Therapeut 2005; 21:969-975.
58. Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52:1397-1402.
59. Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 2007; 67:1521-1530.
60. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? Anevidence-based approach. Arch Intern Med 2006; 166:965-971.
61. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastro-enterology 1998; 115:1335-1339.
62. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625-632.
63. Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol 2008; 42:676-679.
64. Rackoff A, Agrawal A, Hila I, et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 2005; 18:370-373.
65. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroeso-phageal reflux disease. Gastroenterology 2008; 135:1383-1391; 91 e1-5.
66. Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev (Online) 2007; CD003244.
67. Fass R, Sontag SJ, Traxler B, et al. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4:40-56.
68. Hatlebakk J, Katz P, Kuo B, et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40mg daily. Aliment Pharmacol Ther 1998; 12:1235-1240.
69. Frazzoni M, Manno M, De Micheli E, et al. Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors. Dig Liver Dis 2007; 39:415-421.
70. Shimatani T, Moriwaki M, Xu J, et al. Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. Dig Liver Dis 2006; 38:802-808.
71. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation: results from two randomized controlled studies. Aliment Pharmacol Therapeut 2009; 29:731-741.
72. Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with nonerosive reflux disease. Aliment Pharmacol Therapeut 2009; 29: 1261-1272.
73. Blackshaw LA. Receptors and transmission in the brain-gut axis: potential for novel therapies. IV. GABA(B) receptors in the brain-gastroesophageal axis. Am J Physiol 2001; 281:G311-G315.
74. Frisby CL, Mattsson JP, Jensen JM, et al. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by meta-botropic glutamate receptor ligands. Gastroenterology 2005; 129:995-1004.
75. Zhang Q, Lehmann A, Ridga R, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002; 50:19-24.
76. Lidums I, Lehmann A, Checklin H, et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000; 118:7-13.
77. Omari TI, Benninga MA, Sansom L, et al. Effect of baclofen on esophago-gastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr 2006; 149:436-438.
78. Vela MF, Tutuian R, Katz PO, et al. Baclofen decreases acid and nonacid postprandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Therapeut 2003; 17:243-251.
79. Lal R, Sukbuntherng J, Tai EH, et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Experiment Therapeut 2009; 330:911-921.
80. Gerson LB, Huff FJ, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2009 Dec 29 [Epub ahead of print].
81. Keywood C, Wakefield M, Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009; 58:1192-1199.
82. Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease: where next? Aliment Pharmacol Therapeut 2005; 22:79-94.
83. Handa M, Mine K, Yamamoto H, et al. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J Clin Gastro-enterol 1999; 28:228-232.
84. Clouse RE, Lustman PJ, Eckert TC, et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987; 92:1027-1036.
85. Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig Dis Sci 2008; 53:2621-2626.
86. Bromer MQ, Friedenberg F, Miller LS, et al. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc 2005; 61:833-839.
87. Rosenthal R, Peterli R, Guenin MO, et al. Laparoscopic antireflux surgery: long-term outcomes and quality of life. J Laparoscopic Adv Surg Tech A 2006; 16:557-561.
88. Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesopha-geal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006; 93:1483-1487.
89. Becker V, Bajbouj M, Waller K, et al. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors: a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Therapeut 2007; 26:1355-1360.
90. del Genio G, Tolone S, del Genio F, et al. Prospective assessment of patient selection for antireflux surgery by combined multichannel intraluminal impedance pH monitoring. J Gastrointest Surg 2008; 12:1491-1496.
91. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Therapeut 2007; 26:1333-1344.
92. Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Therapeut 2007; 26:443-453.
93. Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Thera-peut 2008; 27:473-482.
94. Chowers Y, Atarot T, Kostadinov A, et al. PPI activity is optimized by VB101, a parietal cell activator. Gastroenterology 2008; 134:A-172.
95. Hunt RH, Armstrong D, Yaghoobi M, et al. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Therapeut 2008; 28:187-199.
96. Hunt RH, Armstrong D, Yaghoobi M, et al. Clinical trials: pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30mg, 60mg and 90mg versus esomeprazole 40mg in healthy male subjects. Aliment Pharmacol Therapeut 2010; 31:648-657.
97. Scarpignato C, Hunt RH. Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol 2008; 8:677-684.
98. Schutze F CS, Ficheux H, Homerin M, et al. [Sidem Pharma]. Pharmaceutical composition combining tenatoprazole and an histamine H2-receptor antagonist. WO 2004/372562004.